Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.

Although treatment of multiple sclerosis (MS) with the type I interferon (IFN) IFN-β lowers disease activity, the role of endogenous type I IFN in MS remains controversial. We studied CD4+ T cells and CD4+ T cell subsets, monocytes and dendritic cells by flow cytometry and analysed the relationship...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Finn Sellebjerg, Martin Krakauer, Signe Limborg, Dan Hesse, Henrik Lund, Annika Langkilde, Helle Bach Søndergaard, Per Soelberg Sørensen
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6a9834ea9d174e548aeecffd4c7d52f9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6a9834ea9d174e548aeecffd4c7d52f9
record_format	dspace
spelling	oai:doaj.org-article:6a9834ea9d174e548aeecffd4c7d52f92021-11-18T07:16:16ZEndogenous and recombinant type I interferons and disease activity in multiple sclerosis.1932-620310.1371/journal.pone.0035927https://doaj.org/article/6a9834ea9d174e548aeecffd4c7d52f92012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22701554/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Although treatment of multiple sclerosis (MS) with the type I interferon (IFN) IFN-β lowers disease activity, the role of endogenous type I IFN in MS remains controversial. We studied CD4+ T cells and CD4+ T cell subsets, monocytes and dendritic cells by flow cytometry and analysed the relationship with endogenous type I IFN-like activity, the effect of IFN-β therapy, and clinical and magnetic resonance imaging (MRI) disease activity in MS patients. Endogenous type I IFN activity was associated with decreased expression of the integrin subunit CD49d (VLA-4) on CD4+CD26(high) T cells (Th1 helper cells), and this effect was associated with less MRI disease activity. IFN-β therapy reduced CD49d expression on CD4+CD26(high) T cells, and the percentage of CD4+CD26(high) T cells that were CD49d(high) correlated with clinical and MRI disease activity in patients treated with IFN-β. Treatment with IFN-β also increased the percentage of CD4+ T cells expressing CD71 and HLA-DR (activated T cells), and this was associated with an increased risk of clinical disease activity. In contrast, induction of CD71 and HLA-DR was not observed in untreated MS patients with evidence of endogenous type IFN I activity. In conclusion, the effects of IFN-β treatment and endogenous type I IFN activity on VLA-4 expression are similar and associated with control of disease activity. However, immune-activating effects of treatment with IFN-β may counteract the beneficial effects of treatment and cause an insufficient response to therapy.Finn SellebjergMartin KrakauerSigne LimborgDan HesseHenrik LundAnnika LangkildeHelle Bach SøndergaardPer Soelberg SørensenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 6, p e35927 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Finn Sellebjerg Martin Krakauer Signe Limborg Dan Hesse Henrik Lund Annika Langkilde Helle Bach Søndergaard Per Soelberg Sørensen Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.
description	Although treatment of multiple sclerosis (MS) with the type I interferon (IFN) IFN-β lowers disease activity, the role of endogenous type I IFN in MS remains controversial. We studied CD4+ T cells and CD4+ T cell subsets, monocytes and dendritic cells by flow cytometry and analysed the relationship with endogenous type I IFN-like activity, the effect of IFN-β therapy, and clinical and magnetic resonance imaging (MRI) disease activity in MS patients. Endogenous type I IFN activity was associated with decreased expression of the integrin subunit CD49d (VLA-4) on CD4+CD26(high) T cells (Th1 helper cells), and this effect was associated with less MRI disease activity. IFN-β therapy reduced CD49d expression on CD4+CD26(high) T cells, and the percentage of CD4+CD26(high) T cells that were CD49d(high) correlated with clinical and MRI disease activity in patients treated with IFN-β. Treatment with IFN-β also increased the percentage of CD4+ T cells expressing CD71 and HLA-DR (activated T cells), and this was associated with an increased risk of clinical disease activity. In contrast, induction of CD71 and HLA-DR was not observed in untreated MS patients with evidence of endogenous type IFN I activity. In conclusion, the effects of IFN-β treatment and endogenous type I IFN activity on VLA-4 expression are similar and associated with control of disease activity. However, immune-activating effects of treatment with IFN-β may counteract the beneficial effects of treatment and cause an insufficient response to therapy.
format	article
author	Finn Sellebjerg Martin Krakauer Signe Limborg Dan Hesse Henrik Lund Annika Langkilde Helle Bach Søndergaard Per Soelberg Sørensen
author_facet	Finn Sellebjerg Martin Krakauer Signe Limborg Dan Hesse Henrik Lund Annika Langkilde Helle Bach Søndergaard Per Soelberg Sørensen
author_sort	Finn Sellebjerg
title	Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.
title_short	Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.
title_full	Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.
title_fullStr	Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.
title_full_unstemmed	Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.
title_sort	endogenous and recombinant type i interferons and disease activity in multiple sclerosis.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/6a9834ea9d174e548aeecffd4c7d52f9
work_keys_str_mv	AT finnsellebjerg endogenousandrecombinanttypeiinterferonsanddiseaseactivityinmultiplesclerosis AT martinkrakauer endogenousandrecombinanttypeiinterferonsanddiseaseactivityinmultiplesclerosis AT signelimborg endogenousandrecombinanttypeiinterferonsanddiseaseactivityinmultiplesclerosis AT danhesse endogenousandrecombinanttypeiinterferonsanddiseaseactivityinmultiplesclerosis AT henriklund endogenousandrecombinanttypeiinterferonsanddiseaseactivityinmultiplesclerosis AT annikalangkilde endogenousandrecombinanttypeiinterferonsanddiseaseactivityinmultiplesclerosis AT hellebachsøndergaard endogenousandrecombinanttypeiinterferonsanddiseaseactivityinmultiplesclerosis AT persoelbergsørensen endogenousandrecombinanttypeiinterferonsanddiseaseactivityinmultiplesclerosis
_version_	1718423669484552192

Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.

Ejemplares similares